New Advances and Treatment in Thrombosis and Endothelial Injury Syndromes
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 1708
Special Issue Editors
Interests: hematology; cellular therapies; endothelial injury; fungal infections; thrombosis; hemophilia
Interests: vascular pathology; endothelial dysfunction; hypertension; cardiovascular diseases; chronic inflammation; autoimmune rheumatic disorders
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiovascular disease (CVD)—mainly arterial and venous thrombotic events—constitutes the leading cause of morbidity and mortality worldwide, not only in the general population but also among patients with chronic disorders such as autoimmune rheumatic diseases (ARDs) and hematological diseases. Despite significant advances in the prevention and management of arterial and venous thrombosis, critical gaps remain in our understanding of the molecular mechanisms that drive thrombotic risk, particularly in special populations. Moreover, the effects of emerging “cardioprotective” therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists, on thrombosis and vascular biology, as well as the molecular pathways underlying these effects, remain poorly understood.
In particular, venous thromboembolism (VTE) represents a complex, multifactorial clinical entity, arising from both congenital and acquired prothrombotic mechanisms. Antiphospholipid syndrome (APS) is among the most common acquired causes of thrombophilia, manifesting with arterial or venous thrombosis, pregnancy morbidity, and microvascular involvement. Microvascular thrombosis is also a defining feature of thrombotic microangiopathies (TMAs), a heterogeneous group of disorders that includes thrombotic thrombocytopenic purpura (TTP), complement-mediated TMA [also referred to as atypical hemolytic uremic syndrome (aHUS)], and secondary TMAs associated with ARDs. In addition, transplant-associated TMA (TA-TMA) is a severe complication observed in recipients of hematopoietic cell transplantation (HCT). Thrombosis may also be the initial manifestation of paroxysmal nocturnal hemoglobinuria (PNH), a rare complement-mediated hematologic disorder. Despite the substantial therapeutic progress, data on the long-term cardiovascular burden and vascular sequelae of these conditions remain limited.
Beyond thrombosis, endothelial dysfunction and injury are central to the pathogenesis of multiple clinical entities, including hypertension, ARDs, and complications related to HCT and novel cellular therapies. In ARDs, accumulating evidence highlights the prognostic and pathogenic role of endothelial injury biomarkers in the development of vascular complications. Importantly, the interplay between endothelial cells, the complement system, and thromboinflammatory pathways suggests that complement activation may represent a shared mechanistic link contributing to thrombosis and cardiovascular complications across diverse clinical settings.
In this context, this Special Issue aims to provide a comprehensive platform for original research and high-quality reviews that advance our understanding of thrombosis, endothelial injury, and cardiovascular disease, with particular emphasis on molecular mechanisms and special populations.
Topics of interest include, but are not limited to, the following:
- Cardiovascular disease and thrombotic complications;
- Arterial and venous thrombosis;
- Endothelial dysfunction and vascular injury;
- Antiphospholipid syndrome and acquired thrombophilia;
- Thrombotic microangiopathies and complement-mediated disorders;
- Cardiovascular disease in autoimmune, hematologic, and transplant populations;
- Molecular and translational insights into thromboinflammation.
Dr. Paschalis Evangelidis
Dr. Panagiota Anyfanti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antiphospholipid syndrome
- autoimmune rheumatic diseases
- cardiovascular disease
- endothelial dysfunction
- hematopoietic cell transplantation
- thromboinflammation
- thrombosis
- thrombotic microangiopathies
- venous thromboembolism
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
